Stockscreener 앱 받기
0.8438
2.85%
-0.0232
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
ONCY: Promising GI cancer data and new patent strategies position pelareorep for major milestones - TradingView
Oncolytics schedules FDA meeting on anal cancer drug pathway - Investing.com
Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention - Yahoo Finance
Oncolytics Biotech (NASDAQ: ONCY) director Stephen Glover files initial Form 3 - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) grants director 30,000 options - Stock Titan
VersaFi ferme les marchés - Barchart.com
ONCOLYTICS BIOTECH (ONCY) CMO awarded 260,000 stock options at $1.06 - Stock Titan
Oncolytics Biotech (ONCY) COO discloses 500,000-share stock option holding - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives 30,000 stock options at $1.06 - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) grants director Rigby 30,000 options - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) director granted options on 30,000 shares at $1.06 - Stock Titan
ONCOLYTICS (ONCY) CFO receives 260,000 stock options at $1.06 exercise price - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) CBO receives 260,000 stock options at $1.06 exercise price - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) CEO awarded 755,000 options at $1.06 strike - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives 30,000 stock options grant at $1.06 - Stock Titan
ONCOLYTICS (NASDAQ: ONCY) director awarded stock options on 30,000 shares - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) CTO awarded 260,000 stock options at $1.06 strike - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives stock options on 30,000 shares - Stock Titan
145,000 stock options granted to Oncolytics (ONCY) COO McAdory - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) director receives 96,000 stock options at $1.06 - Stock Titan
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
Why Oncolytics Biotech (ONCY) Is Up 14.5% After New Pelareorep RAS-Tumor Immune Activation Data - Sahm
Oncolytics Biotech Appoints Steve Glover to Board and Promotes John McAdory to COO - geneonline.com
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics appoints Glover to board, promotes McAdory to COO - Investing.com UK
Signs of Abundant Global Supplies Undercut Sugar Prices - Barchart.com
Wall Street May Still Be Looking at the Old Oncolytics Story - Barchart.com
Best Compounded Tirzepatide Online Provider (2026) Report Published by Kinross Research - Barchart.com
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer - The IFP
Oncolytics appoints Glover to board, promotes McAdory to COO By Investing.com - Investing.com Canada
Oncolytics Biotech® Announces Appointment of Steve Glover - GlobeNewswire
Oncolytics (ONCY) Reports Promising Preclinical Study Results - GuruFocus
Oncolytics Biotech Reports Positive Preclinical Data for Pelareorep and RAS Inhibitor Combo in Solid Tumors - Minichart
Oncolytics Biotech (Nasdaq: ONCY) posts early pelareorep RAS-combo data - Stock Titan
Lab data show stronger RAS cancer combo; pancreatic, colorectal studies next - Stock Titan
How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks? - Barchart.com
From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story - ACCESS Newswire
ONCY Stock Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
ONCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
Analyst Jared Kelly Highlights Potential Opportunities for Oncolytics Biotech in Oncology Sector - geneonline.com
H.C. Wainwright reiterates Oncolytics Biotech stock rating at buy - Investing.com UK
H.C. Wainwright reiterates Oncolytics Biotech stock rating at buy By Investing.com - Investing.com Australia
Oncolytics (ONCY) to Present Key Trial Data at 2026 ASCO Annual Meeting - GuruFocus
Oncolytics Biotech Reports New Clinical Data on Pelareorep for Pancreatic and Gastrointestinal Cancers in 2026 8-K Filing - Minichart
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech (Nasdaq: ONCY) shows pelareorep immune activation data at ASCO 2026 - Stock Titan
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors - GlobeNewswire
New cancer immunotherapy linked to tumor volume drops at ASCO - Stock Titan
ONCY Stock Price, Quote & Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Let - GuruFocus
ONCY: Aligns with FDA on pivotal trial for Pelareorep in anal cancer - MSN
ONCY: Aligns with FDA on Pivotal Trial for Pelareorep in Anal Cancer - Yahoo Finance
ONCY Technical Analysis | Trend, Signals & Chart Patterns | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
ONCY Should I Buy - Intellectia AI
Oncolytics Biotech Inc.Common Stock (NQ: ONCY - FinancialContent
0.12%
0.82%
자본화:
|
볼륨(24시간):